Castelli C, Sensi M, Lupetti R, Mortarini R, Panceri P, Anichini A, Parmiani G
Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.
Cancer Res. 1994 Sep 1;54(17):4785-90.
To assess whether RAS oncogenes may affect the expression of cytokines in tumor cells, the presence of interleukins (IL) 1 alpha, 1 beta, 4, 6, 7, and 8, tumor necrosis factor (TNF) alpha and interferon gamma mRNA has been analyzed by reverse transcriptase-polymerase chain reaction in 19 melanoma clones derived from the metastatic cell line 665/2 and previously characterized for RAS mutation and expression. Five of these clones and the parental cell line showed a mutation at codon 61 of N-RAS that resulted in Gln-->Arg substitution (N-RAS/61+), while in the remaining 14, only the wild-type allele for N-RAS was present (N-RAS/61-). With the exception of interferon gamma and IL-4, all the cytokines tested were expressed by the parental 665/2 cell line, whereas IL-1 alpha, IL-6, and TNF-alpha were coordinately transcribed only in the subset of the clones bearing the mutated N-RAS gene. The other cytokine genes studied (IL-1 beta, IL-4, IL-7, and IL-8) displayed a variable degree of expression, and such an heterogeneity was not correlated to the N-RAS phenotype of the clones. The association between N-RAS oncogene and IL-1 alpha, IL-6, and TNF-alpha expression was also found in a 665/2 subline (665/2/5) in which loss of mutated N-RAS genes simultaneously occurred with the loss of IL-1 alpha, IL-6, and TNF-alpha expression. Direct evidence that N-RAS oncogene could influence the pattern of cytokine expression was provided by the coordinate induction of IL-1 alpha, IL-6, and TNF-alpha messenger RNA achieved in N-RAS/61+ transfectants of the N-RAS wild-type melanoma clone 2/21. Furthermore, IL-1 alpha, IL-6, and TNF-alpha could be detected by enzyme-linked immunosorbent assay in the culture medium obtained from N-RAS/61+ melanoma clones as well as from positive transfectants, indicating that lymphokine mRNA expression triggered by the activated N-RAS oncogene lead to a secreted protein. In an N-RAS/61+ melanoma clone, by adding specific antibodies against each cytokine, it was found that soluble IL-1 alpha exerted a positive control on IL-6 mRNA and a negative one on its own expression. In addition, IL-1 alpha and IL-6 were negatively regulated by soluble IL-6 and TNF-alpha.
为评估RAS癌基因是否可能影响肿瘤细胞中细胞因子的表达,通过逆转录-聚合酶链反应分析了19个源自转移性细胞系665/2且先前已对RAS突变和表达进行表征的黑色素瘤克隆中白细胞介素(IL)1α、1β、4、6、7和8、肿瘤坏死因子(TNF)α及干扰素γ mRNA的存在情况。这些克隆中有5个以及亲本细胞系在N-RAS的61密码子处发生了突变,导致谷氨酰胺(Gln)替换为精氨酸(Arg)(N-RAS/61+),而其余14个克隆中仅存在N-RAS的野生型等位基因(N-RAS/61-)。除干扰素γ和IL-4外,所检测的所有细胞因子均由亲本665/2细胞系表达,而IL-1α、IL-6和TNF-α仅在携带突变N-RAS基因的克隆亚群中协同转录。所研究的其他细胞因子基因(IL-1β、IL-4、IL-7和IL-8)表现出不同程度的表达,且这种异质性与克隆的N-RAS表型无关。在一个665/2亚系(665/2/5)中也发现了N-RAS癌基因与IL-1α、IL-6和TNF-α表达之间的关联,在该亚系中,突变的N-RAS基因丢失同时伴随着IL-1α、IL-6和TNF-α表达的丧失。N-RAS野生型黑色素瘤克隆2/21的N-RAS/61+转染子中IL-1α、IL-6和TNF-α信使RNA的协同诱导提供了直接证据,证明N-RAS癌基因可影响细胞因子表达模式。此外,通过酶联免疫吸附测定可在源自N-RAS/61+黑色素瘤克隆以及阳性转染子的培养基中检测到IL-1α、IL-6和TNF-α,这表明由活化的N-RAS癌基因触发的淋巴因子mRNA表达导致了一种分泌蛋白的产生。在一个N-RAS/61+黑色素瘤克隆中,通过添加针对每种细胞因子的特异性抗体发现,可溶性IL-1α对IL-6 mRNA发挥正调控作用,而对其自身表达发挥负调控作用。此外,IL-1α和IL-6受到可溶性IL-6和TNF-α的负调控。